HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

DX 619

an anti-infective agent; structure in first source

Also Known As:

DX-619; DX619 compound

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - DX 619: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        DX 619: 3

Experts

1.	Higashiyama, Yasuhito: 2 articles (09/2006 - 01/2006)
2.	Hirakata, Yoichi: 2 articles (09/2006 - 01/2006)
3.	Kohno, Shigeru: 2 articles (09/2006 - 01/2006)
4.	Miyazaki, Yoshitsugu: 2 articles (09/2006 - 01/2006)
5.	Mizuta, Yohei: 2 articles (09/2006 - 01/2006)
6.	Tomono, Kazunori: 2 articles (09/2006 - 01/2006)
7.	Tsukamoto, Kazuhiro: 2 articles (09/2006 - 01/2006)
8.	Yanagihara, Katsunori: 2 articles (09/2006 - 01/2006)
9.	Hiramatsu, Keiichi: 1 article (12/2007)
10.	Ito, Teruyo: 1 article (12/2007)

Related Diseases

1.	Pneumonia (Pneumonitis) 01/01/2006 - "Our results suggest that DX-619 and sitafloxacin are potent against both PSSP and PRSP in our mouse pneumonia model." 01/01/2006 - "Against PRSP-mediated pneumonia in mice, the ED50s of DX-619, sitafloxacin, and ciprofloxacin were 0.69, 4.84, and 38.75 mg/kg, respectively. "
2.	Infections 09/01/2006 - "Our results emphasise the potency of DX-619 against MRSA and VISA murine haematogenous pulmonary infection." 01/01/2006 - "In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model." 09/01/2006 - "In this study, the potency of DX-619, a novel des-fluoro(6)-quinolone agent, was compared with that of vancomycin (VCM) in a murine model of haematogenous bronchopneumonia infection caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. " 09/01/2006 - "Treatment with DX-619 resulted in a significant decrease in the number of viable bacteria in the MRSA infection model (mean+/-standard error of the mean for control, VCM and DX-619 groups: 7.97+/-0.32, 7.19+/-0.33 and 2.91+/-0.60 log(10) colony-forming units/lung, respectively). " 01/01/2006 - "In murine lung infections caused by PSSP, the 50% effective doses (ED50s) of DX-619, sitafloxacin, and ciprofloxacin were 9.15, 11.1, and 127.6 mg/kg of body weight, respectively. "
3.	Bronchopneumonia 09/01/2006 - "Potency of DX-619, a novel des-F(6)-quinolone, in haematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus." 09/01/2006 - "In this study, the potency of DX-619, a novel des-fluoro(6)-quinolone agent, was compared with that of vancomycin (VCM) in a murine model of haematogenous bronchopneumonia infection caused by methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate S. "
4.	Body Weight (Weight, Body) 01/01/2006 - "In murine lung infections caused by PSSP, the 50% effective doses (ED50s) of DX-619, sitafloxacin, and ciprofloxacin were 9.15, 11.1, and 127.6 mg/kg of body weight, respectively. "

Related Drugs and Biologics

1.	sitafloxacin
2.	Vancomycin
3.	Quinolones
4.	Levofloxacin (Levaquin)
5.	Teicoplanin
6.	Anti-Bacterial Agents (Antibiotics)
7.	Linezolid (Zyvox)
8.	quinupristin-dalfopristin (Synercid)
9.	arbekacin
10.	DX 619